查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1883237

全球載體篩檢市場

Carrier Screening
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球病毒帶因者篩檢市場預計到2030年將達到78億美元

全球帶因者篩檢市場規模在2024年估計為33億美元，預計到2030年將達到78億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為15.6%。本報告分析的細分市場之一－遺傳疾病細分市場，預計複合年成長率將達到18.8%，並在分析期結束時達到30億美元。囊腫纖維化細分市場預計在分析期間內複合年成長率將達到16.5%。

美國市場規模估計為8.659億美元，而中國市場預計將以21.5%的複合年成長率成長。

預計到2024年，美國病毒帶因者篩檢市場規模將達8.659億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到19億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到21.5%。其他值得關注的區域市場包括日本和加拿大，預計在分析期內，這兩個國家的複合年成長率將分別達到10.9%和13.2%。在歐洲，德國預計將以約12.2%的複合年成長率成長。

全球載體篩檢市場—主要市場趨勢與促進因素概述

為什麼攜帶者篩檢是現代醫學的重要工具？

帶因者篩檢是一項重要的基因檢測流程，它可以幫助個人和夫妻確定是否擁有者某些遺傳疾病的基因，即使他們本身沒有任何症狀。這項篩檢在生育計畫中發揮重要作用，使準父母能夠評估他們將囊腫纖維化、戴-薩克斯病和鐮狀細胞貧血等遺傳疾病遺傳給子女的風險。隨著人們對遺傳健康的認知不斷提高，攜帶者篩檢已成為孕前和產前保健的基石，使人們有機會做出知情的生育決定。在個人化醫療和預防性醫療保健蓬勃發展的時代，攜帶者篩檢為早期發現和主動健康管理提供了一種強大的工具，使家庭能夠在懷孕前降低風險。攜帶者篩檢的價值在於它提供的詳細基因資訊，幫助人們了解自身的基因相容性。這些資訊可以指南夫妻就遺傳諮詢、輔助生殖技術（例如體外受精（IVF）結合基因檢測）以及其他生育策略做出明智的選擇。隨著基因技術的進步和可篩檢疾病的增加，攜帶者篩檢正變得越來越普遍，使更多家庭能夠獲得重要的基因訊息，篩檢預防嚴重的傳播。

技術創新如何改進了帶因者篩檢？

技術創新顯著提升了攜帶者篩檢的效率，使其速度更快、成本更低、覆蓋範圍更廣。其中一項最具突破性的進展是次世代定序（NGS），它能夠同時分析多個基因，從而降低成本並擴大篩檢疾病的範圍。 NGS 使得更廣泛、更詳細的帶因者篩檢方案成為可能，一次檢測即可檢測數百種遺傳疾病。這大大提高了攜帶者篩檢的準確性和覆蓋範圍，使夫妻能夠全面了解自身的遺傳風險，並就生育計劃做出明智的決定。家用基因檢測套組的廣泛普及也徹底改變了攜帶者篩檢的途徑，人們可以在家中採集 DNA 樣本，並在經認證的實驗室進行分析。這些試劑盒的便利性和易用性使得更多人能夠進行基因檢測，不受居住限制。基於生物資訊學的遺傳數據分析技術的進步，以及人工智慧（AI）的融合應用，進一步提高了檢測結果的準確性，減少了人為誤差的可能性，並提供了更快、更可靠的遺傳資訊。隨著人工智慧的發展，預計它將在提高攜帶者篩檢結果的準確性和預測能力方面發揮更重要的作用，進一步擴大其在生殖醫學領域的應用範圍。

哪些新興趨勢正在影響病毒攜帶者篩檢市場？

隨著技術進步和醫療重點的轉變，基因檢測方法也在不斷變化，目前有幾個關鍵趨勢正在影響攜帶者篩檢市場。其中一個關鍵趨勢是向「擴展型帶因者篩檢」的轉變，即在檢測項目中納入更廣泛的遺傳疾病。傳統的帶因者篩檢僅關注少數幾種疾病，而如今，技術進步使得單次檢測即可涵蓋數百種遺傳疾病。這種擴展型篩檢方法越來越受歡迎，因為它能更全面地了解遺傳風險，使個人及其醫療保健提供者能夠做出更明智的決定。另一個新興趨勢是將攜帶者篩檢融入個人化醫療。隨著醫療保健環境向個人化治療方案轉變，基因檢測不僅用於生育計劃，還用於疾病預防。此外，攜帶者篩檢正日益被推薦為普遍服務，適用於所有計劃生育的人群，無論其種族背景或家族病史如何。這種普及帶因者篩檢的趨勢使得更多高風險夫妻能夠及早被發現，從而採取積極措施，降低將嚴重遺傳疾病遺傳給後代的可能性。值得注意的是，遺傳諮詢的角色正隨著攜帶者篩檢的發展而不斷擴大。隨著攜帶者篩檢結果日益複雜，遺傳諮詢師在解讀結果、幫助人們了解其對生殖健康的影響方面發揮著至關重要的作用。此外，諸如線上入口網站和遠端醫療等數位化工具的普及，使得攜帶者篩檢和遺傳諮詢服務更容易遠端獲取，進一步擴大了這些重要醫療服務的覆蓋範圍。

哪些因素正在推動病毒攜帶者篩檢市場的成長？

攜帶者篩檢市場的成長受多種因素驅動，主要包括基因技術的進步、人們對遺傳疾病認知的提高以及醫療實踐的不斷發展。其中一個關鍵促進因素是人們對遺傳健康在計劃生育中重要性的認知不斷提高。隨著越來越多的人了解遺傳在疾病預防中的作用，對攜帶者篩檢的需求顯著成長。醫療保健提供者和遺傳諮詢師的教育工作正在將攜帶者篩檢確立為孕前和孕期保健的重要組成部分，尤其對於那些有將遺傳疾病遺傳給後代風險的夫婦而言。基因檢測技術的進步，特別是次世代定序（NGS）技術的進步，降低了攜帶者篩檢的成本和周轉時間，使其惠及更多人。這些技術進步，加上家用基因檢測套組的便利性，降低了進入門檻，鼓勵更多人積極主動管理自體生殖健康。此外，醫療保健專業人員建議所有準父母進行普遍帶因者篩檢，這一趨勢透過增加尋求基因檢測服務的人數，進一步擴大了市場。監管和保險覆蓋範圍的改善也是推動市場成長的因素。許多國家現在提供攜帶者篩檢的保險報銷，使個人能夠更輕鬆地負擔得起。此外，隨著越來越多的醫療機構將帶因者篩檢納入常規生殖健康服務，市場預計將持續成長。最後，個人化和預防性醫療的興起，使得攜帶者篩檢成為確保子孫後代健康的重要工具。個人化和預防性醫療根據個人的基因譜提供量身定做的醫療服務。這些因素，以及基因研究領域的不斷創新，正在推動攜帶者篩檢在全球範圍內的持續成長和廣泛應用。

部分：

檢測類型（分子篩檢、生化篩檢）；疾病類型（遺傳性疾病、囊腫纖維化、脊髓性肌肉萎縮症、高雪氏症、戴-薩克斯病、鐮狀細胞疾病、其他疾病類型）

受訪公司範例

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有採用查詢LLM 或產業專用的SLM 的典型方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片文字稿、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在國、製造地以及進出口（成品和OEM產品）情況，預測企業競爭格局的變化。這種複雜多變的市場現實將對競爭對手產生多方面的影響，包括銷貨成本增加、盈利下降和供應鏈重組，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 亞太其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP10911

Global Carrier Screening Market to Reach US$7.8 Billion by 2030

The global market for Carrier Screening estimated at US$3.3 Billion in the year 2024, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Genetic Disorders, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Cystic Fibrosis segment is estimated at 16.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$865.9 Million While China is Forecast to Grow at 21.5% CAGR

The Carrier Screening market in the U.S. is estimated at US$865.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Carrier Screening Market - Key Trends and Drivers Summarized

Why Is Carrier Screening a Vital Tool in Modern Healthcare?

Carrier screening is a critical genetic testing process that helps individuals and couples determine if they carry genes for certain inherited disorders, even if they show no symptoms themselves. This screening plays a vital role in reproductive planning, allowing prospective parents to assess the risk of passing genetic conditions, such as cystic fibrosis, Tay-Sachs disease, and sickle cell anemia, to their children. With increasing awareness of genetic health, carrier screening has become a cornerstone of preconception and prenatal care, offering individuals a chance to make informed reproductive decisions. In an era where personalized medicine and preventive care are gaining momentum, carrier screening offers a powerful tool for early detection and proactive health management, allowing families to mitigate risks before conception. The value of carrier screening lies in the detailed genetic insights it provides, helping people understand their genetic compatibility. This information can guide couples toward informed choices such as genetic counseling, assisted reproductive technologies like in vitro fertilization (IVF) with genetic testing, or other reproductive strategies. As genetic technologies advance and the number of conditions identifiable through screening expands, carrier screening is becoming increasingly mainstream, ensuring that more families have access to crucial genetic information that can prevent the transmission of severe disorders.

How Have Technological Advances Enhanced Carrier Screening?

Technological innovations have significantly improved carrier screening, making it faster, more affordable, and more comprehensive. One of the most transformative advancements is next-generation sequencing (NGS), which allows for the analysis of multiple genes simultaneously, increasing the scope of conditions screened for while reducing costs. With NGS, broader and more detailed carrier screening panels are available, testing for hundreds of genetic conditions in a single analysis. This has dramatically improved the accuracy and scope of carrier screening, ensuring that couples receive a comprehensive understanding of their genetic risks and can make well-informed decisions regarding family planning. The rise of at-home genetic testing kits has also revolutionized access to carrier screening, allowing individuals to collect DNA samples at home and send them to certified labs for analysis. The convenience and accessibility of these kits have made it easier for a larger population to undergo genetic testing, regardless of their location. Along with improvements in genetic data analysis through bioinformatics, the integration of artificial intelligence (AI) is further enhancing the precision of test results, reducing the potential for human error, and offering faster, more reliable genetic insights. As AI continues to evolve, it is expected to play an even more critical role in improving the accuracy and predictive power of carrier screening results, further expanding its use in reproductive health.

What Emerging Trends Are Impacting the Carrier Screening Market?

Several important trends are currently shaping the carrier screening market, as advancements in technology and shifting healthcare priorities drive changes in how genetic testing is approached. One of the key trends is the move toward expanded carrier screening, where a broader range of genetic conditions is included in testing panels. Traditionally, carrier screening focused on a limited set of disorders, but advancements in technology now allow for the inclusion of hundreds of genetic conditions in a single test. This expanded screening approach is gaining popularity as it provides a more comprehensive picture of genetic risks, enabling individuals and healthcare providers to make more informed decisions. Another emerging trend is the integration of carrier screening into personalized medicine. As the healthcare landscape shifts toward individualized treatment plans, genetic testing is being used not only for reproductive planning but also to prevent genetic conditions before they develop. In addition, carrier screening is increasingly being recommended as a universal service for all individuals planning to have children, regardless of ethnic background or family history. This trend toward universal carrier screening is helping to ensure that more at-risk couples are identified early, allowing for proactive measures to be taken to reduce the likelihood of transmitting serious genetic conditions to their offspring. The growing role of genetic counseling alongside carrier screening is also noteworthy. As the complexity of carrier screening results increases, genetic counselors are becoming integral to the process, helping individuals interpret results and understand the implications for their reproductive health. Additionally, the rise of digital tools, such as online portals and telemedicine, is making it easier for individuals to access both carrier screening and genetic counseling services remotely, further expanding the reach of this essential healthcare service.

What Factors Are Behind the Growth of the Carrier Screening Market?

The growth in the carrier screening market is driven by several factors, primarily linked to advances in genetic technologies, increased awareness of genetic disorders, and evolving healthcare practices. One of the key drivers is the growing awareness of the importance of genetic health in family planning. As more people understand the role genetics plays in disease prevention, the demand for carrier screening has increased significantly. Educational efforts from healthcare providers and genetic counselors have helped normalize carrier screening as an essential part of preconception and prenatal care, particularly for couples who are at risk of passing on genetic disorders. Advancements in genetic testing technologies, especially next-generation sequencing (NGS), have reduced the cost and turnaround time for carrier screening, making it more accessible to a broader population. These technological improvements, combined with the convenience of at-home genetic testing kits, have lowered barriers to entry, encouraging more individuals to take proactive steps in managing their reproductive health. Moreover, the trend toward universal carrier screening, recommended by healthcare professionals for all prospective parents, has expanded the market by increasing the number of people seeking genetic testing services. Regulatory and insurance coverage improvements have also fueled market growth. Many countries now offer insurance reimbursement for carrier screening, making it more affordable for individuals. Additionally, as more healthcare providers adopt carrier screening as part of routine reproductive health services, the market is poised for continued expansion. Finally, the rise of personalized and preventive medicine, where healthcare is tailored to individual genetic profiles, is positioning carrier screening as a critical tool for ensuring healthier outcomes for future generations. These factors, along with ongoing innovations in genetic research, are driving the continued growth and adoption of carrier screening across the globe.

SCOPE OF STUDY:

The report analyzes the Carrier Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Molecular Screening Test, Biochemical Screening Test); Disease Type (Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease, Other Disease Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Carrier Screening - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Genetic Disorders Propels Growth in the Carrier Screening Market
    • Advances in Genomic Technologies Drive the Accuracy and Accessibility of Carrier Screening
    • Growing Adoption of Carrier Screening in Preconception and Prenatal Care Strengthens the Business Case for Genetic Testing
    • Technological Innovations in Next-Generation Sequencing (NGS) Accelerate Demand for Comprehensive Carrier Screening
    • Rising Incidence of Inherited Genetic Disorders Spurs Market Growth in Carrier Screening
    • Growing Demand for Personalized Medicine Generates Opportunities for Carrier Screening in Tailored Healthcare
    • Integration of AI and Data Analytics in Genetic Testing Enhances Efficiency and Interpretation of Carrier Screening Results
    • Rising Healthcare Expenditure and Insurance Coverage for Genetic Testing Sustain Growth in Carrier Screening Services
    • Expanding Use of Carrier Screening in Fertility Treatments Drives Demand in Assisted Reproductive Technology (ART)
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Tay-Sachs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Molecular Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Biochemical Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Carrier Screening Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • JAPAN
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • CHINA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • EUROPE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • GERMANY
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • INDIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030
  • AFRICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2015, 2025 & 2030

IV. COMPETITION